New discovered molecular markers as promising therapeutic targets in germ cell tumors

Bibliography

• Oosterhuis JW, Looijenga LH. Testicular germ-cell tumors in a broader perspective. Nat Rev Cancer 2005;5:210-22
   PubMed Web of Science ®Google Scholar
• Chieffi P, Franco R, Portella G. Molecular and cell biology of testicular germ cell tumors. Int Rev Cell Mol Biol 2009;278:277-308
   PubMed Web of Science ®Google Scholar
• Chieffi P, Chieffi S, Franco R, Sinisi A. Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment. J Endocrinol Invest 2012;35:1015-20
   PubMed Web of Science ®Google Scholar
• Chieffi P, Chieffi S. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumours: an overview. J Cell Physiol 2013;228:1641-6
   PubMed Web of Science ®Google Scholar
• Hanna NH, Einhorn LH. Testicular cancer. N Engl J Med 2014;371:2005-16
   PubMed Web of Science ®Google Scholar
• Jones RH, Vasey PA. Part II: testicular cancer—management of advanced disease. Lancet Oncol 2003;4:738-47
   PubMed Web of Science ®Google Scholar
• Skakkebaek NE. Possible carcinoma-in-situ of the testis. Lancet 1972;2:2516-17
   Google Scholar
• Rajpert-De Meyts E, Skakkebaek NE. Pathogenesis of testicular carcinoma in situ and germ cell cancer: still more questions than answers. Int J Androl 2011;34:e2-6
   Google Scholar
• Skakkebaek NE, Berthelsen JG, Giwercman A, Muller J. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987;10:19-28
   PubMed Web of Science ®Google Scholar
• Lutke Holzik MF, Rapley EA, Hoekstra HJ, et al. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol 2004;5:363-71
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293-8
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Fossà SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:125-32
   Web of Science ®Google Scholar
• Chung P, Parker C, Panzarella T, et al. Surveillance in stage I testicular seminoma. Can J Urol 2002;9:1637-40
   PubMedGoogle Scholar
• Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in diffential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005;18:561-79
   Web of Science ®Google Scholar
• Bahrami A, Ro JY, Ayala AG. An overview of testicular germ cell tumors. Arch Pathol Lab Med 2006;131:1267-80
   Web of Science ®Google Scholar
• Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008;299:672-84
   PubMed Web of Science ®Google Scholar
• Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14:2638-45
   PubMed Web of Science ®Google Scholar
• Chieffi P, Chieffi S. An up-date on newly discovered immunohistochemical biomarkers for the diagnosis of human testicular germ cell tumors. Histol Histopathol 2014;29:999-1006
   PubMed Web of Science ®Google Scholar
• Chieffi P. Molecular targets for the treatment of testicular germ cell tumors. Mini Rev Med Chem 2007;7:755-9
   PubMed Web of Science ®Google Scholar
• Chieffi P, Battista S, Barchi M, et al. HMGA1 and HMGA2 protein expression in mouse spermatogenesis. Oncogene 2002;21:3644-50
   PubMed Web of Science ®Google Scholar
• Franco R, Esposito F, Fedele M, et al. Detection of high mobility group proteins A1 and A2 represents a valid diagnostic marker in post-puberal testicular germ cell tumours. J Pathol 2008;214:58-64
   PubMed Web of Science ®Google Scholar
• Pero R, Lembo F, Di Vizio D, et al. RNF4 is a growth inhibitor expressed in germ cells and lost in human testicular tumours. Am J Pathol 2001;159:1225-30
   PubMed Web of Science ®Google Scholar
• Pero R, Lembo F, Chieffi P, et al. Translational regulation of a novel testis-specific RNF4 transcript. Mol Reprod Dev 2003;66:1-7
   PubMed Web of Science ®Google Scholar
• Fedele M, Franco R, Salvatore G, et al. PATZ1 gene has a critical role in the spermatogenesis and testicular tumours. J Pathol 2008;215:39-47
   PubMed Web of Science ®Google Scholar
• Esposito F, Boscia F, Franco R, et al. Down-regulation of estrogen receptor-β associates with transcriptional coregulator PATZ1 delocalization in human testicular seminomas. J Pathol 2011;224:110-20
   PubMed Web of Science ®Google Scholar
• Esposito F, Boscia F, Gigantino V, et al. The high mobility group A1-oestrogen receptor β nuclear interaction is impaired in human testicular seminomas. J Cell Physiol 2012;227:3749-55
   PubMed Web of Science ®Google Scholar
• Di Agostino S, Fedele M, Chieffi P, et al. Phosphorylation of high mobility group protein A2 by Nek kinase during the first meiotic division in mouse spermatocytes. Mol Biol Cell 2004;15:1224-32
   PubMed Web of Science ®Google Scholar
• Barbagallo F, Paronetto MP, Franco R, et al. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas. J Pathol 2009;217:431-41
   PubMed Web of Science ®Google Scholar
• Naro C, Barbagallo F, Chieffi P, et al. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res 2014;42:3218-27
   PubMed Web of Science ®Google Scholar
• Ledford H. Doubts raised over stem-cell marker. Nature 2007;449:647
   PubMed Web of Science ®Google Scholar
• Atlasi Y, Mowla SJ, Ziaee SA, et al. OCT4 spliced variants are differentially expressed in human pluripotent and non-pluripotent cells. Stem Cells 2008;26:3068-74
   PubMed Web of Science ®Google Scholar
• Avilion AA, Nicolis SK, Pevny LH, et al. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003;17:126-40
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Kimura H, Tada M, et al. Nanog expression in mouse germ cell development. Gene Expr Patterns 2005;5:639-46
   PubMed Web of Science ®Google Scholar
• Voutsadakis IA. The chemosensitivity of testicular germ cell tumors. Cell oncol 2014;37:79-94
   PubMed Web of Science ®Google Scholar
• Cao D, Allan RW, Cheng L, et al. RNA-binding protein LIN28 is a marker for testicular germ cell tumors. Hum Pathol 2011;42:710-18
   PubMed Web of Science ®Google Scholar
• Hart AH, Hartley L, Parker K, et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 2005;104:2092-8
   PubMed Web of Science ®Google Scholar
• de Jong J, Stoop H, Gillis AJ, et al. Differential expression of SOX17 and SOX2 in germ cells and stem cells has biological and clinical implications. J Pathol 2008;215:21-30
   PubMed Web of Science ®Google Scholar
• Kim I, Saunders TL, Morrison SJ. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 2007;130:470-83
   PubMed Web of Science ®Google Scholar
• Vicini E, Loiarro M, Di Agostino S, et al. 17--estradiol elicits genomic and non-genomic responses in mouse male germ cells. J Cell Physiol 2006;206:238-45
   PubMed Web of Science ®Google Scholar
• Franco R, Boscia F, Gigantino V, et al. GPR30 is over-expressed in post puberal testicular germ cell tumors. Cancer Biol Ther 2011;11:609-13
   PubMed Web of Science ®Google Scholar
• Boscia F, Passaro C, Gigantino V, et al. High levels of GPR30 protein in human testicular carcinoma in situ and seminomas correlate with low levels of estrogen receptor-beta and indicate a switch in estrogen responsiveness. J Cell Physiol 2015;230:1290-7
   PubMed Web of Science ®Google Scholar
• Chieffi P. GPR30 is a potential therapeutic target in human carcinoma in situ and seminomas. Receptors Clin Inv 2015;2:e676
   Google Scholar
• Meng X, de Rooij DG, Westerdahl K, et al. Promotion of seminomatous tumors by targeted overexpression of glial cell line-derived neurotrophic factor in mouse testis. Cancer Res 2001;61:3267-71
   PubMed Web of Science ®Google Scholar
• Staibano S, Ilardi G, Leone V, et al. Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. BMC Cancer 2013;13:433
   PubMed Web of Science ®Google Scholar
• Shiokawa M, Masutani M, Fujihara H, et al. Genetic alteration of Poly (ADP-ribose) polymerase-1 in human germ cell tumors. Jpn J Clin Oncol 2005;35:97-102
   PubMed Web of Science ®Google Scholar
• Usanova S, Piée-Staffa A, Sied U, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010;9:248
   PubMed Web of Science ®Google Scholar
• Hill BT, Scanlon KJ, Hansson J, et al. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 1994;30:832-7
   Web of Science ®Google Scholar
• Tsuchiya N, Mishina M, Narita J, et al. Association of XRCC1 gene polymorphisms with the susceptibility and chromosomal aberration of testicular germ cell tumors. Int J oncol 2006;28:1217-23
   PubMed Web of Science ®Google Scholar
• Litchfield K, Summersgill B, Yost S, et al. Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nature Commun 2015;6:5973
   PubMed Web of Science ®Google Scholar
• Chen YT, Chiu R, Lee P, et al. Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum Reprod 2011;26:3232-43
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54
   PubMed Web of Science ®Google Scholar
• Chieffi P, Troncone G, Caleo A, et al. Aurora B expression in normal testis and seminomas. J Endocrinol 2004;181:263-70
   PubMed Web of Science ®Google Scholar
• Esposito F, Libertini S, Franco R, et al. Aurora B expression in post-puberal testicular germ cell tumours. J Cell Physiol 2009;221:435-9
   PubMed Web of Science ®Google Scholar
• Portella G, Passaro C, Chieffi P. Aurora B: a new prognostic marker and therapeutic target in cancer. Curr Med Chem 2011;18:482-96
   PubMed Web of Science ®Google Scholar
• Hauf S, Cole RW, La Terra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-94
   PubMed Web of Science ®Google Scholar
• Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7
   PubMed Web of Science ®Google Scholar
• Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36
   PubMed Web of Science ®Google Scholar
• Terada Y, Tatsuka M, Suzuki F, et al. AIM-1: a mammalian midbody-associated protein required forcytokinesis. EMBO J 1998;17:667-76
   PubMed Web of Science ®Google Scholar
• Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002;62:5168-77
   PubMed Web of Science ®Google Scholar
• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87
   PubMed Web of Science ®Google Scholar
• Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004;164:305-13
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Heinrich MC, et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006;29:12-13
   PubMed Web of Science ®Google Scholar
• Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs 2010;28:523-8
   PubMed Web of Science ®Google Scholar
• Palumbo C, van Roozendaal K, Gillis AJ, et al. Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms. J Pathol 2002;196:467-77
   PubMed Web of Science ®Google Scholar
• Manova K, Nocka K, Besmer P, Bachvarova RF. Gonadal expression of c-kit encoded at the W locus of the mouse. Development 1990;110:1057-69
   PubMed Web of Science ®Google Scholar
• Sorrentino V, Giorgi M, Geremia R, et al. Expression of the c-kit proto-oncogene in the murine male germ cells. Oncogene 1991;6:149-51
   PubMed Web of Science ®Google Scholar
• McCoshen JA, McCallion DJ. A study of the primordial germ cells during their migratory phase in Steel mutant mice. Experientia 1975;31:589-90
   PubMedGoogle Scholar
• Loveland KL, Schlatt S. Stem cell factor and c-kit in the mammalian testis: lessons originating from Mother Nature’s gene knockouts. J Endocrinol 1997;153:337-44
   PubMed Web of Science ®Google Scholar
• Looijenga LH, de Leeuw H, van Oorschot M, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003;63:7674-8
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703
   PubMed Web of Science ®Google Scholar
• Di Vizio D, Cito L, Boccia A, et al. Loss of tumour suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene 2005;24:1882-94
   PubMed Web of Science ®Google Scholar
• Viglietto G, Romano A, Maglione D, et al. Neovascularization inhuman germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996;13:577-87
   PubMed Web of Science ®Google Scholar
• Fukuda S, Shirahama T, Imazono Y, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999;85:1323-30
   PubMed Web of Science ®Google Scholar
• Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996;32:2534-9
   Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
   PubMed Web of Science ®Google Scholar
• Zakarija A, Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 2005;6:578-83
   Web of Science ®Google Scholar
• Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005;2:562-77
   PubMedGoogle Scholar
• Ranieri G, Patruno R, Ruggirei E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;1:1845-7
   Web of Science ®Google Scholar
• Jain A, Brames MJ, Vaughn DJ, Einhorn LH. Phase II clinical trial of oxaliplatin and bevacizumab in refractory germ cell tumors. Am J Clin Oncol 2014;37:450-3
   PubMed Web of Science ®Google Scholar
• Lee D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin Lung Cancer 2005;7:89-91
   PubMed Web of Science ®Google Scholar
• Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet 2003;35:215-17
   PubMed Web of Science ®Google Scholar
• Maatouk DM, Loveland KL, McManus MT, et al. Dicer1 is required for differentiation of the mouse male germline. Biol Reprod 2008;79:696-703
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124:1169-81
   PubMed Web of Science ®Google Scholar
• Langroudi L, Jamshidi-Adegani F, Shafiee A, et al. MiR-371-373 cluster acts as a tumor-suppressor-miR and promotes cell cycle arrest in unrestricted somatic stem cells. Tumour Biol 2015. [Epub ahead of print]
   Google Scholar
• Kedde M, Strasser MJ, Boldajipour B, et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 2007;131:1273-86
   PubMed Web of Science ®Google Scholar
• Linger R, Dudakia D, Huddart R, et al. Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chrom Cancer 2008;47:247-52
   PubMed Web of Science ®Google Scholar